<DOC>
	<DOCNO>NCT00003656</DOCNO>
	<brief_summary>RATIONALE : Tretinoin may help kidney cancer cell develop normal cell . Interferon alfa may interfere growth cancer cell . PURPOSE : Phase II trial study effectiveness liposomal tretinoin plus interferon alfa treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>Tretinoin Plus Interferon Alfa Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response patient metastatic renal cell carcinoma treat tretinoin liposome interferon alfa-2b . - Determine toxicity regimen patient . - Study retinoic acid receptor expression tissue obtain select patient tumor biopsy . OUTLINE : This dose-escalation study tretinoin liposome concurrent individual dose escalation interferon alfa-2b . ( Phase I close accrual 9/24/03 . ) Patients receive tretinoin liposome IV 30 minute weekly interferon alfa-2b subcutaneously five consecutive day ( M-F ) 8 week . Courses repeat every 8 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos tretinoin liposome maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine additional patient accrue treated dose . ( Phase I close accrual 9/24/03 . ) During first 3 week study , patient receive interferon alfa-2b weekly dose escalation . After week 3 , patient continue high acceptable dose level interferon alfa-2b remainder study . ( Phase I close accrual 9/24/03 . ) Patients follow 30 day last treatment . PROJECTED ACCRUAL : A total 3-18 patient accrued phase I portion study ( Phase I close accrual 9/24/03 ) . A total 14-25 patient accrue phase II portion study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic renal cell carcinoma Bidimensionally measurable disease No active brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 No coagulation disorder Hepatic : Bilirubin le 1.5 mg/dL SGOT SGPT le 112.5 IU/L less 2.5 time upper limit normal No clinically significant hepatic disease , include autoimmune hepatitis Renal : Creatinine le 2 mg/dL OR Creatinine clearance great 50 mL/min No clinically significant renal disease Cardiovascular : No clinically significant cardiac disease No thrombophlebitis Pulmonary : No severe debilitate pulmonary disease No pulmonary embolism Other : No history diabetes mellitus prone ketoacidosis No known hypersensitivity retinoids retinoic acid derivative interferon component injection study No thyroid abnormality hinder maintain thyroid function normal range No severe infection No severe malnutrition No clinically significant retinal abnormality No preexist psychiatric condition , especially depression history severe psychiatric disorder No concurrent malignancy except nonmelanoma skin cancer curatively treat carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use 2 effective method contraception 1 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy : No 1 prior biological response modifier therapy immunotherapy Chemotherapy : No 1 prior chemotherapy regimen Endocrine therapy : No concurrent steroids Radiotherapy : At least 4 week since prior radiotherapy Surgery : At least 4 week since prior major surgery Other : No prior retinoid therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>